Latest Caligan Partners LP Stock Portfolio
Caligan Partners LP Performance:
2025 Q3: 58.37%YTD: 82.65%2024: 25.42%
Performance for 2025 Q3 is 58.37%, and YTD is 82.65%, and 2024 is 25.42%.
About Caligan Partners LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Caligan Partners LP reported an equity portfolio of $763.5 Millions as of 30 Sep, 2025.
The top stock holdings of Caligan Partners LP are LQDA, , . The fund has invested 24.2% of it's portfolio in LIQUIDIA CORPORATION and 16.1% of portfolio in ABIVAX SA.
The fund managers got completely rid off VERONA PHARMA PLC (VRNA), Y-MABS THERAPEUTICS INC (YMAB) and REZOLUTE INC (RZLT) stocks. They significantly reduced their stock positions in MERUS N V (MRUS) and ABIVAX SA. Caligan Partners LP opened new stock positions in ADMA BIOLOGICS INC (ADMA), XENON PHARMACEUTICALS INC (XENE) and AVALO THERAPEUTICS INC (AVTX). The fund showed a lot of confidence in some stocks as they added substantially to TYRA BIOSCIENCES INC (TYRA), REVOLUTION MEDICINES INC (RVMD) and MINERALYS THERAPEUTICS INC.
The top stock holdings of Caligan Partners LP are LQDA, , . The fund has invested 24.2% of it's portfolio in LIQUIDIA CORPORATION and 16.1% of portfolio in ABIVAX SA.
The fund managers got completely rid off VERONA PHARMA PLC (VRNA), Y-MABS THERAPEUTICS INC (YMAB) and REZOLUTE INC (RZLT) stocks. They significantly reduced their stock positions in MERUS N V (MRUS) and ABIVAX SA. Caligan Partners LP opened new stock positions in ADMA BIOLOGICS INC (ADMA), XENON PHARMACEUTICALS INC (XENE) and AVALO THERAPEUTICS INC (AVTX). The fund showed a lot of confidence in some stocks as they added substantially to TYRA BIOSCIENCES INC (TYRA), REVOLUTION MEDICINES INC (RVMD) and MINERALYS THERAPEUTICS INC.
Caligan Partners LP Annual Return Estimates Vs S&P 500
Our best estimate is that Caligan Partners LP made a return of 58.37% in the last quarter. In trailing 12 months, it's portfolio return was 97.87%.
New Buys
| Ticker | $ Bought |
|---|---|
| adma biologics inc | 38,652,700 |
| xenon pharmaceuticals inc | 17,849,300 |
| avalo therapeutics inc | 10,591,700 |
| inhibrx biosciences inc | 7,961,380 |
| verrica pharmaceuticals inc | 3,982,050 |
New stocks bought by Caligan Partners LP
Additions
| Ticker | % Inc. |
|---|---|
| tyra biosciences inc | 266 |
| revolution medicines inc | 67.12 |
| mineralys therapeutics inc | 37.44 |
| evolus inc | 23.85 |
| aura biosciences inc | 13.59 |
| agios pharmaceuticals inc | 5.6 |
Additions to existing portfolio by Caligan Partners LP
Reductions
| Ticker | % Reduced |
|---|---|
| merus n v | -66.98 |
| abivax sa | -13.29 |
Caligan Partners LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| verrica pharmaceuticals inc | -4,897,660 |
| y-mabs therapeutics inc | -10,565,200 |
| rezolute inc | -6,881,840 |
| verona pharma plc | -135,900,000 |
| biocryst pharmaceuticals inc | -5,724,620 |
Caligan Partners LP got rid off the above stocks
Sector Distribution
Caligan Partners LP has about 67.2% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 67.2 |
| Others | 32.8 |
Market Cap. Distribution
Caligan Partners LP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 32.8 |
| MID-CAP | 32.6 |
| SMALL-CAP | 32.6 |
| NANO-CAP | 1.5 |
Stocks belong to which Index?
About 51.7% of the stocks held by Caligan Partners LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 51.7 |
| Others | 48.3 |
Caligan Partners LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Caligan Partners LP
Caligan Partners LP has 16 stocks in it's portfolio. About 88.2% of the portfolio is in top 10 stocks. EOLS proved to be the most loss making stock for the portfolio. was the most profitable stock for Caligan Partners LP last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ADMA | adma biologics inc | 5.06 | 2,636,610 | 38,652,700 | new | |||
| AGIO | agios pharmaceuticals inc | 5.95 | 1,131,200 | 45,406,600 | added | 5.6 | ||
| ANIK | anika therapeutics inc | 1.77 | 1,435,130 | 13,490,200 | unchanged | 0.00 | ||
| AURA | aura biosciences inc | 0.18 | 227,174 | 1,403,940 | added | 13.59 | ||
| AVTX | avalo therapeutics inc | 1.39 | 833,333 | 10,591,700 | new | |||
| BCRX | biocryst pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| EOLS | evolus inc | 3.33 | 4,138,940 | 25,413,100 | added | 23.85 | ||
| EXEL | exelixis inc | 8.25 | 1,525,730 | 63,012,600 | unchanged | 0.00 | ||
| LQDA | liquidia corporation | 24.18 | 8,118,890 | 184,624,000 | unchanged | 0.00 | ||
| MRUS | merus n v | 2.67 | 216,954 | 20,426,200 | reduced | -66.98 | ||
| RVMD | revolution medicines inc | 6.51 | 1,064,250 | 49,700,400 | added | 67.12 | ||
| RZLT | rezolute inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| TYRA | tyra biosciences inc | 1.28 | 696,825 | 9,748,580 | added | 266 | ||
| VRCA | verrica pharmaceuticals inc | 0.52 | 923,910 | 3,982,050 | new | |||
| VRCA | verrica pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| VRNA | verona pharma plc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| XENE | xenon pharmaceuticals inc | 2.34 | 444,565 | 17,849,300 | new | |||
| YMAB | y-mabs therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| abivax sa | 16.14 | 1,451,920 | 123,268,000 | reduced | -13.29 | |||
| mineralys therapeutics inc | 13.77 | 2,772,650 | 105,139,000 | added | 37.44 | |||